MDT
Medtronic plc NYSE Listed May 2, 1973$77.95
After hrs
$76.15
+0.00%
Mkt Cap $100.1B
52w Low $77.16
2.7% of range
52w High $106.33
50d MA $87.13
200d MA $93.98
P/E (TTM)
22.0x
EV/EBITDA
14.6x
P/B
2.1x
Debt/Equity
0.6x
ROE
9.2%
P/FCF
20.9x
RSI (14)
—
ATR (14)
—
Beta
0.76
50d MA
$87.13
200d MA
$93.98
Avg Volume
8.6M
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Building Two, Parkmore Business Park West · Galway 2 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | 1.34 | 1.36 | +1.5% | 96.41 | -0.4% | +2.2% | +1.2% | +0.5% | +2.3% | +0.4% | — |
| Nov 18, 2025 | AMC | 1.31 | 1.36 | +3.8% | 100.80 | +0.2% | -0.5% | -1.4% | +0.4% | +2.4% | +4.5% | — |
| Aug 19, 2025 | AMC | 1.23 | 1.26 | +2.4% | 89.90 | +0.5% | +3.7% | +1.3% | +3.1% | +2.4% | +2.5% | — |
| May 21, 2025 | AMC | 1.58 | 1.62 | +2.5% | 84.41 | -1.3% | -4.1% | -4.4% | -3.8% | -3.8% | -2.4% | — |
| Feb 18, 2025 | AMC | 1.36 | 1.39 | +2.2% | 86.07 | -0.1% | +1.1% | +2.2% | +4.5% | +4.8% | +5.1% | — |
| Nov 19, 2024 | AMC | 1.25 | 1.26 | +0.8% | 85.00 | -0.3% | -1.0% | -0.3% | +1.4% | +0.9% | +0.8% | — |
| Aug 20, 2024 | AMC | 1.20 | 1.23 | +2.5% | 85.38 | +0.6% | +2.5% | +2.9% | +3.5% | +4.6% | +4.0% | — |
| May 23, 2024 | AMC | 1.45 | 1.46 | +0.7% | 81.38 | -0.5% | +1.1% | +0.8% | +0.1% | -1.0% | -0.0% | — |
| Feb 20, 2024 | AMC | 1.26 | 1.30 | +3.2% | 85.85 | +0.8% | +0.1% | -0.9% | -0.2% | -2.5% | -2.3% | — |
| Nov 21, 2023 | AMC | 1.18 | 1.25 | +5.9% | 78.62 | +0.4% | -0.3% | +0.4% | +0.5% | +0.0% | +0.3% | — |
| Aug 22, 2023 | AMC | 1.11 | 1.20 | +8.1% | 83.72 | +1.1% | -0.0% | -3.2% | -1.8% | -2.8% | -2.0% | — |
| May 25, 2023 | AMC | 1.56 | 1.57 | +0.6% | 83.54 | -0.9% | -2.5% | -1.2% | -0.9% | -0.9% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | UBS | Maintains | Neutral → Neutral | — | $82.00 | $82.90 | +1.1% | +1.5% | +2.2% | +1.6% | +1.1% | -0.1% |
| Apr 15 | Truist | Maintains | Hold → Hold | — | $88.12 | $87.86 | -0.3% | -1.2% | -2.8% | -2.2% | -3.5% | -6.9% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $87.21 | $87.00 | -0.2% | +0.9% | +1.0% | -0.1% | -1.8% | -1.2% |
| Apr 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $88.65 | $87.91 | -0.8% | -0.8% | -1.6% | -0.7% | -0.6% | -1.7% |
| Apr 7 | Citigroup | Maintains | Buy → Buy | — | $86.28 | $85.99 | -0.3% | +0.2% | +2.7% | +1.9% | +1.1% | +2.0% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $86.63 | $86.43 | -0.2% | -0.4% | -0.2% | +2.3% | +1.5% | +0.7% |
| Apr 6 | Argus | Maintains | Buy → Buy | — | $86.63 | $86.43 | -0.2% | -0.4% | -0.2% | +2.3% | +1.5% | +0.7% |
| Apr 1 | Barclays | Maintains | Overweight → Overweight | — | $86.65 | $86.58 | -0.1% | -0.7% | -0.0% | -0.4% | -0.3% | +2.3% |
| Apr 1 | Piper Sandler | Maintains | Neutral → Neutral | — | $86.65 | $86.58 | -0.1% | -0.7% | -0.0% | -0.4% | -0.3% | +2.3% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $87.89 | $87.30 | -0.7% | -0.3% | -0.9% | -2.4% | -1.4% | -2.1% |
| Mar 10 | Needham | Maintains | Buy → Buy | — | $91.34 | $91.21 | -0.1% | -1.6% | -2.6% | -4.3% | -4.6% | -3.4% |
| Feb 18 | JP Morgan | Maintains | Neutral → Neutral | — | $96.41 | $96.00 | -0.4% | +2.2% | +1.2% | +0.5% | +2.3% | +0.4% |
| Feb 18 | Barclays | Maintains | Overweight → Overweight | — | $96.41 | $96.00 | -0.4% | +2.2% | +1.2% | +0.5% | +2.3% | +0.4% |
| Feb 18 | Baird | Maintains | Neutral → Neutral | — | $96.41 | $96.00 | -0.4% | +2.2% | +1.2% | +0.5% | +2.3% | +0.4% |
| Feb 17 | Needham | Maintains | Buy → Buy | — | $99.49 | $95.88 | -3.6% | -3.1% | -1.0% | -1.9% | -2.6% | -0.9% |
| Feb 9 | Needham | Upgrade | Hold → Buy | — | $102.90 | $103.59 | +0.7% | -1.2% | -1.4% | -1.8% | -2.0% | -3.3% |
| Feb 4 | UBS | Maintains | Neutral → Neutral | — | $103.18 | $103.32 | +0.1% | -1.3% | -0.2% | -0.3% | -1.5% | -1.7% |
| Jan 9 | Bernstein | Maintains | Outperform → Outperform | — | $98.69 | $98.95 | +0.3% | -1.2% | -1.8% | -2.3% | +0.1% | +0.3% |
| Jan 8 | Barclays | Maintains | Overweight → Overweight | — | $99.77 | $99.62 | -0.2% | -1.1% | -2.2% | -2.8% | -3.4% | -1.0% |
| Jan 6 | William Blair | Upgrade | Market Perform → Outperform | — | $97.36 | $98.06 | +0.7% | +3.0% | +2.5% | +1.4% | +0.2% | -0.4% |
| Dec 18 | Truist | Maintains | Hold → Hold | — | $98.30 | $98.69 | +0.4% | +0.2% | +0.3% | -0.6% | -0.8% | -1.0% |
| Nov 20 | Barclays | Maintains | Overweight → Overweight | — | $100.34 | $100.37 | +0.0% | -1.0% | +0.9% | +2.9% | +5.0% | +4.7% |
| Nov 20 | Truist | Maintains | Hold → Hold | — | $100.34 | $100.37 | +0.0% | -1.0% | +0.9% | +2.9% | +5.0% | +4.7% |
| Nov 19 | UBS | Maintains | Neutral → Neutral | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.4% | +0.4% | +2.4% | +4.5% |
| Nov 19 | RBC Capital | Maintains | Outperform → Outperform | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.4% | +0.4% | +2.4% | +4.5% |
| Nov 19 | Goldman Sachs | Upgrade | Sell → Neutral | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.4% | +0.4% | +2.4% | +4.5% |
| Nov 19 | Baird | Maintains | Neutral → Neutral | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.4% | +0.4% | +2.4% | +4.5% |
| Nov 19 | Wells Fargo | Maintains | Overweight → Overweight | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.4% | +0.4% | +2.4% | +4.5% |
| Nov 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.4% | +0.4% | +2.4% | +4.5% |
| Nov 13 | JP Morgan | Maintains | Neutral → Neutral | — | $95.81 | $95.00 | -0.8% | +0.3% | +0.1% | +0.5% | +5.2% | +4.7% |
| Oct 15 | Truist | Maintains | Hold → Hold | — | $96.54 | $96.07 | -0.5% | -1.2% | -1.6% | -0.8% | -0.6% | -0.7% |
| Oct 9 | Stifel | Maintains | Hold → Hold | — | $97.87 | $98.19 | +0.3% | -1.4% | -2.5% | -2.3% | -1.4% | -2.6% |
| Oct 7 | Citigroup | Maintains | Buy → Buy | — | $98.43 | $98.33 | -0.1% | -0.1% | -0.6% | -2.0% | -3.0% | -2.9% |
| Aug 26 | Argus | Maintains | Buy → Buy | — | $92.04 | $92.43 | +0.4% | +0.2% | +0.0% | -0.1% | +0.8% | +1.4% |
| Aug 21 | Truist | Maintains | Hold → Hold | — | $93.22 | $93.32 | +0.1% | -2.3% | -0.5% | -1.3% | -1.1% | -1.3% |
| Aug 21 | Citigroup | Maintains | Buy → Buy | — | $93.22 | $93.32 | +0.1% | -2.3% | -0.5% | -1.3% | -1.1% | -1.3% |
| Aug 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $89.90 | $90.36 | +0.5% | +3.7% | +1.3% | +3.1% | +2.4% | +2.5% |
| Aug 20 | Bernstein | Maintains | Outperform → Outperform | — | $89.90 | $90.36 | +0.5% | +3.7% | +1.3% | +3.1% | +2.4% | +2.5% |
| Aug 20 | Baird | Maintains | Neutral → Neutral | — | $89.90 | $90.36 | +0.5% | +3.7% | +1.3% | +3.1% | +2.4% | +2.5% |
| Aug 20 | UBS | Maintains | Neutral → Neutral | — | $89.90 | $90.36 | +0.5% | +3.7% | +1.3% | +3.1% | +2.4% | +2.5% |
| Aug 14 | Needham | Maintains | Hold → Hold | — | $92.91 | $92.85 | -0.1% | -1.0% | +0.1% | -0.1% | -3.2% | +0.3% |
| Jul 16 | Mizuho | Maintains | Outperform → Outperform | — | $89.22 | $89.59 | +0.4% | +0.6% | +0.3% | +0.4% | +0.5% | +2.7% |
| Jul 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $89.73 | $89.70 | -0.0% | -0.6% | +0.1% | -0.2% | -0.1% | -0.0% |
| Jul 9 | Citigroup | Maintains | Buy → Buy | — | $88.58 | $88.83 | +0.3% | +0.5% | +0.9% | +1.5% | +1.3% | +0.7% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $87.67 | $87.56 | -0.1% | +1.0% | +1.5% | +2.0% | +2.6% | +2.3% |
| Jun 30 | Wolfe Research | Upgrade | Underperform → Peer Perform | — | $86.02 | $86.65 | +0.7% | +1.3% | +3.2% | +2.6% | +2.8% | +1.9% |
| Jun 6 | Needham | Maintains | Hold → Hold | — | $87.00 | $87.29 | +0.3% | +0.5% | +0.5% | +1.1% | +1.2% | +1.7% |
| May 22 | Needham | Maintains | Hold → Hold | — | $84.41 | $83.28 | -1.3% | -4.1% | -4.4% | -3.8% | -3.8% | -2.4% |
| May 22 | RBC Capital | Maintains | Outperform → Outperform | — | $84.41 | $83.28 | -1.3% | -4.1% | -4.4% | -3.8% | -3.8% | -2.4% |
| May 22 | Mizuho | Maintains | Outperform → Outperform | — | $84.41 | $83.28 | -1.3% | -4.1% | -4.4% | -3.8% | -3.8% | -2.4% |
No insider trades available.
8-K · 7.01
! Medium
Medtronic plc -- 8-K 7.01: Regulation FD Disclosure
Medtronic experienced a cybersecurity breach but reports no impact to products, operations, or patient safety, mitigating near-term investor concerns about operational disruption.
Apr 27
8-K · 7.01
! Medium
MiniMed Group, Inc. -- 8-K 7.01: Regulation FD Disclosure
Medtronic disclosed an unauthorized third-party breach of its IT systems; the company activated incident response protocols and engaged external cybersecurity experts to investigate and remediate the security breach.
Apr 27
8-K · 5.02
!!! Very High
SkinHealth Systems Inc. -- 8-K 5.02: Executive Change
SkinHealth Systems appointed Kenneth Tripp as director and Dr. Sachin Shridharani as Senior Vice President, signaling management strengthening under new leadership.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Vafa Jamali's appointment as director signals potential strategic shifts in governance and decision-making, warranting investor attention to board composition changes affecting corporate direction and oversight quality.
Apr 6
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I cannot provide a meaningful analysis of this filing because the summary provided is incomplete and contains only procedural language referencing exhibits rather than details about the actual executive change, compensation, or departure rationale.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Medtronic will face $0.04 per-share dilution in Q4 FY2026 from its MiniMed IPO, creating near-term EPS headwinds that investors should factor into earnings estimates.
Mar 24
8-K · 5.02
!!! Very High
MiniMed Group, Inc. -- 8-K 5.02: Executive Change
Brian Sandstrom's resignation as director of MiniMed Group signals potential leadership transitions that investors should monitor for impact on board oversight and strategic direction.
Mar 9
8-K · 5.02
!!! Very High
Shoulder Innovations, Inc. -- 8-K 5.02: Executive Change
Shoulder Innovations replaced director Pardo with Andrew Hykes as Class I director, signaling potential strategic shifts in board composition and governance oversight.
Mar 2
8-K
Medtronic plc -- 8-K Filing
Medtronic exceeded Q3 guidance with $9.0 billion in revenue (8.7% reported growth) and $1.36 non-GAAP EPS, while maintaining full-year FY26 guidance and achieving strong 80% growth in Cardiac Ablation Solutions.
Feb 17
Data updated apr 26, 2026 11:43am
· Source: massive.com